Beijing University of Chinese Medicine, Beijing 100029, China.
Department of Orthopaedic Surgery, Beijing Key Lab Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Beijing 100029, China.
Biomed Res Int. 2021 Apr 30;2021:2191926. doi: 10.1155/2021/2191926. eCollection 2021.
Knee osteoarthritis (KOA) is a common disease in aged adults. Intra-articular (IA) injection of platelet-rich plasma (PRP) therapy is an effective minimally invasive treatment for KOA. We aimed to compare the efficacy and safety of platelet-rich plasma (PRP) with placebo or other conservative treatments.
We conducted a meta-analysis to identify relevant articles from online register databases such as PubMed, Medline, Embase, and the Cochrane Library. The primary outcomes were the visual analogue scale (VAS) score, Western Ontario and McMaster Universities Arthritis Index (WOMAC) score, and International Knee Documentation Committee (IKDC) subjective score. The secondary outcome was the adverse event rate.
A total of 895 articles were identified, of which 23 randomized controlled trials that met the inclusion criteria were determined as eligible. Compared with placebo, PRP had a lower VAS score and higher IKDC subjective score at the 6 month after treatment and significantly less WOMAC score during the follow-up period. Compared with oral NSAIDs, PRP gained a lower WOMAC score at the 6 month after treatment. The VAS score decreased after treatment when reaching PRP and CS. As compared to the HA, the VAS score, WOMAC score, and IKDC subjective score all revealed better PRP results. There were no significant differences in adverse event rates comparing PRP versus placebo or HA. Different PRP applications did not show significant differences in VAS score in the 1 month and WOMAC score in the 3 month after treatment.
To compare with the conservative treatments mentioned above, PRP is more effective in relieving symptoms. There were no significant differences between triple PRP application and single PRP application in short-term curative effect.
膝骨关节炎（KOA）是一种常见的老年疾病。关节内（IA）注射富含血小板的血浆（PRP）疗法是治疗 KOA 的一种有效微创治疗方法。我们旨在比较 PRP 与安慰剂或其他保守治疗的疗效和安全性。
我们进行了荟萃分析，以从在线注册数据库（如 PubMed、Medline、Embase 和 Cochrane 图书馆）中识别相关文章。主要结局指标是视觉模拟评分（VAS）评分、西安大略和麦克马斯特大学关节炎指数（WOMAC）评分和国际膝关节文献委员会（IKDC）主观评分。次要结局指标是不良事件发生率。
共确定了 895 篇文章，其中有 23 项符合纳入标准的随机对照试验被确定为合格。与安慰剂相比，PRP 在治疗后 6 个月时的 VAS 评分和 IKDC 主观评分更高，在随访期间的 WOMAC 评分更低。与口服 NSAIDs 相比，PRP 在治疗后 6 个月时的 WOMAC 评分更低。在 PRP 和 CS 治疗后，VAS 评分下降。与 HA 相比，VAS 评分、WOMAC 评分和 IKDC 主观评分均显示 PRP 效果更好。PRP 与安慰剂或 HA 相比，不良事件发生率无显著差异。不同的 PRP 应用在治疗后 1 个月的 VAS 评分和治疗后 3 个月的 WOMAC 评分方面没有显著差异。
与上述保守治疗相比，PRP 在缓解症状方面更有效。在短期疗效方面，三联 PRP 应用与单 PRP 应用之间没有显著差异。
